Spatial transcriptomics is a powerful tool for creating a detailed map of not just how genes are expressed in a piece of tissue, but also where genetic activity takes place in different cells and locations within the tissue. ...
Aug 31, 2026
0
6
In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the genetic aberrations and microenvironmental peculiarities of tumors and their constituent cells. Such ...
Aug 31, 2026
0
7
Triple-negative breast cancer (TNBC) has a frustrating ability to adapt. Although this aggressive form of breast cancer can initially respond well to chemotherapy, cancer cells often find ways to survive, allowing the disease ...
Aug 31, 2026
0
9
Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. Chemotherapy before or after surgery remains the standard treatment regimen for stage I–III TNBC. Only a small portion of patients can benefit ...
Aug 31, 2026
0
4
A new phase 1 clinical trial has found that an emerging immunotherapy is promising for treating recurrent glioblastoma, a highly aggressive and fatal brain cancer. Chimeric antigen receptor T (CAR-T) cell therapy is a form ...
Aug 31, 2026
0
40
Deep within the cellular landscape, a quiet failure was taking place, impeding a potentially successful form of cancer treatment. For years, scientists hoped an essential part of the innate immune system that detects foreign ...
Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their medication after their heart recovers, and most won't need to continue treatment long term, according ...
Aug 30, 2026
0
27
Men with prostate cancer have a high risk of heart disease, especially when treated with hormone therapy. A large international, first-of-its-kind study led by Hamilton researchers found that routine referrals to an internist ...
Aug 30, 2026
0
389
Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell ...
Aug 29, 2026
0
9
A newly developed radiotheranostic pair, 68Ga/177Lu-NYM096, can identify tumors and effectively deliver targeted radiotherapy to patients with metastatic clear cell renal cell carcinoma (ccRCC). Using a small-molecule compound, ...
Aug 29, 2026
0
7
